NKGen Biotech (NYSE:NKGN) Shares Up 4%

NKGen Biotech, Inc. (NYSE:NKGN)’s stock price shot up 4% during trading on Tuesday . The company traded as high as $1.32 and last traded at $1.31. 112,609 shares traded hands during trading, a decline of 96% from the average session volume of 2,600,783 shares. The stock had previously closed at $1.26.

NKGen Biotech Stock Performance

The stock’s fifty day moving average price is $1.59.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NKGen Biotech stock. Northern Trust Corp bought a new stake in NKGen Biotech, Inc. (NYSE:NKGN) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 15,722 shares of the company’s stock, valued at approximately $43,000. Northern Trust Corp owned approximately 0.07% of NKGen Biotech as of its most recent filing with the Securities & Exchange Commission. 76.17% of the stock is owned by hedge funds and other institutional investors.

NKGen Biotech Company Profile

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.